The Asia Pacific Digital Diabetes Management Market is expected to witness market growth of 12.6% CAGR during the forecast period (2022-2028).
Diabetes is now regarded as one of the world's most serious health problems. Every year, more people are diagnosed with this disease, which can lead to issues later in life. Patient with this disease must adjust their lifestyle and develop behaviors that will help them regulate their glucose levels. Patients with diabetes typically require insulin (by syringe, pen, or pump) as well as blood glucose monitoring equipment. It is critical for patients to maintain track of their health data in order to make decisions in their self-management routines; this information also aids health providers in making treatment decisions.
Diabetes self-care goods and services have evolved over time. The fourth industrial revolution, often known as Industry 4.0, has an impact on all industries, including healthcare. Digital technologies for self-management of this chronic condition have been created in recent years, simplifying diabetes treatment with functionalities such as tailoring treatment for each patient and improving and expediting communication between the patient and the healthcare provider.
The Asia Pacific region is also witnessing many product launches. For example, in May 2019, Roche Diabetes Care India launched its Integrated Diabetes Management Solution (IDMS) program in India with the release of the Accu-Chek Instant blood glucose monitoring (BGM) system and the My Sugar app. The combination marks the entry of next-generation BGM systems. Diabetes is quickly approaching the status of a possible epidemic in India, with more than 62 million diabetic people now diagnosed.
The China market dominated the Asia Pacific Digital Diabetes Management Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $2,459.5 million by 2028. The Japan market is poised to grow at a CAGR of 11.9% during (2022 - 2028). Additionally, The India market is expected to display a CAGR of 13.2% during (2022 - 2028).
Based on Type, the market is segmented into Wearables and Handheld Devices. Based on Product & Service, the market is segmented into Devices (Continuous Glucose Monitoring (CGM) Systems, Smart Glucose Meters, Smart Insulin Pens, and Smart Insulin Pumps/Closed-loop Pumps & Smart Insulin Patches), Application (Diabetes & Blood Glucose Tracking Apps and Obesity & Diet Management Apps), Data Management Software & Platforms, and Services. Based on End User, the market is segmented into Self/Home Healthcare, Hospitals & Specialty Diabetes Clinics, and Academic & Research Institutes. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Abbott Laboratories, Terumo Corporation, F. Hoffmann-La Roche Ltd., DexCom, Inc., Novo Nordisk A/S, ACON Laboratories, Inc., Bayer AG, B. Braun Melsungen AG, and Azumio, Inc.
Diabetes is now regarded as one of the world's most serious health problems. Every year, more people are diagnosed with this disease, which can lead to issues later in life. Patient with this disease must adjust their lifestyle and develop behaviors that will help them regulate their glucose levels. Patients with diabetes typically require insulin (by syringe, pen, or pump) as well as blood glucose monitoring equipment. It is critical for patients to maintain track of their health data in order to make decisions in their self-management routines; this information also aids health providers in making treatment decisions.
Diabetes self-care goods and services have evolved over time. The fourth industrial revolution, often known as Industry 4.0, has an impact on all industries, including healthcare. Digital technologies for self-management of this chronic condition have been created in recent years, simplifying diabetes treatment with functionalities such as tailoring treatment for each patient and improving and expediting communication between the patient and the healthcare provider.
The Asia Pacific region is also witnessing many product launches. For example, in May 2019, Roche Diabetes Care India launched its Integrated Diabetes Management Solution (IDMS) program in India with the release of the Accu-Chek Instant blood glucose monitoring (BGM) system and the My Sugar app. The combination marks the entry of next-generation BGM systems. Diabetes is quickly approaching the status of a possible epidemic in India, with more than 62 million diabetic people now diagnosed.
The China market dominated the Asia Pacific Digital Diabetes Management Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $2,459.5 million by 2028. The Japan market is poised to grow at a CAGR of 11.9% during (2022 - 2028). Additionally, The India market is expected to display a CAGR of 13.2% during (2022 - 2028).
Based on Type, the market is segmented into Wearables and Handheld Devices. Based on Product & Service, the market is segmented into Devices (Continuous Glucose Monitoring (CGM) Systems, Smart Glucose Meters, Smart Insulin Pens, and Smart Insulin Pumps/Closed-loop Pumps & Smart Insulin Patches), Application (Diabetes & Blood Glucose Tracking Apps and Obesity & Diet Management Apps), Data Management Software & Platforms, and Services. Based on End User, the market is segmented into Self/Home Healthcare, Hospitals & Specialty Diabetes Clinics, and Academic & Research Institutes. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Abbott Laboratories, Terumo Corporation, F. Hoffmann-La Roche Ltd., DexCom, Inc., Novo Nordisk A/S, ACON Laboratories, Inc., Bayer AG, B. Braun Melsungen AG, and Azumio, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Wearables
- Handheld Devices
By Product & Service
- Devices
- Continuous Glucose Monitoring (CGM) Systems
- Smart Glucose Meters
- Smart Insulin Pens
- Smart Insulin Pumps/Closed-loop Pumps & Smart Insulin Patches
- Application
- Diabetes & Blood Glucose Tracking Apps
- Obesity & Diet Management Apps
- Data Management Software & Platforms
- Services
By End User
- Self/Home Healthcare
- Hospitals & Specialty Diabetes Clinics
- Academic & Research Institutes
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Medtronic PLC
- Abbott Laboratories
- Terumo Corporation
- F. Hoffmann-La Roche Ltd.
- DexCom, Inc.
- Novo Nordisk A/S
- ACON Laboratories, Inc.
- Bayer AG
- B.Braun Melsungen AG
- Azumio, Inc.
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. Asia Pacific Digital Diabetes Management Market by Type
Chapter 5. Asia Pacific Digital Diabetes Management Market by Product & Service
Chapter 6. Asia Pacific Digital Diabetes Management Market by End User
Chapter 7. Asia Pacific Digital Diabetes Management Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Medtronic PLC
- Abbott Laboratories
- Terumo Corporation
- F. Hoffmann-La Roche Ltd.
- DexCom, Inc.
- Novo Nordisk A/S
- ACON Laboratories, Inc.
- Bayer AG
- B. Braun Melsungen AG
- Azumio, Inc.
Methodology
LOADING...
